It is with profound sadness that we share the passing of Rebecca Lambert Bent, Founder, President, and Executive Chair of NED Biosystems, who died peacefully and surrounded by her family on August 11 following a short illness.
Rebecca worked passionately and, with her characteristic tenacity, sought to advance a systems-based approach to cancer treatment globally. As President and CEO, she led the development of the company’s oral cancer protocol, NED-170, and guided NED-170 through crucial preparation for its clinical trial. Her vision was shaped by decades of entrepreneurial, civic, and public service leadership, and by her commitment to addressing late-stage cancers in a fundamentally different way.
Those within Rebecca’s magnetic orbit knew her as a determined and original thinker whose energy, conviction, and ability to bring people together helped build the foundation on which the company stands today. Her work with respected scientific leaders, including her original mentor Judah Folkman, MD, and more recently DNA sequencer inventor LeRoy Hood, MD, PhD, among others, reflected both her ambition for NED and her belief that meaningful progress in treating complex diseases requires collaboration across disciplines.
On behalf of the entire NED team and Board, we extend our deepest condolences to Rebecca’s family and all who knew and loved her.
We remain committed to honoring Rebecca’s legacy by continuing the work she began with care, discipline, and purpose. NED’s Board has confirmed effective immediately that the Company’s leadership roles are as follows: Geoffrey Ling, MD, PhD, Col (Ret) is Chair of the Board of Directors; José Miguel Trevejo, MD, PhD is serving as Interim CEO; Elinor Mullins is President; and Mary Davis is Treasurer.
As we seek to realize Rebecca’s vision that all cancer patients have access to treatment that provides quality-of-life, lacks toxicity, and allows them to remain productive members of their community, we are more dedicated than ever to advancing NED-170 into its phase 2a clinical trial on a path that honors her hard work.
A longtime resident of Washington, CT, and summer resident of Nantucket, MA, Rebecca was born in Binghamton, NY, daughter of Dr. Abol Hassan and Eleanor Fotouhi.
She attended Williams College and graduated from Simmons College with a bachelor’s degree in political science in 1969. She completed Harvard Business School’s advanced management program in 1982, where she was the sole woman in her class and also ran the Boston Marathon.
She was a longtime congregant and vestry member of St. John’s Church, in Washington, CT, and St. Paul’s Church on Nantucket.
She leaves her husband Ted, her son, Max (Holly) of Richmond, VA, and their two children, and a daughter, Insha Afsar.
Rebecca founded NED Biosystems, a public benefit corporation, to develop her unique systems-approach to cancer treatment which is now preparing for a clinical trial.
Earlier in her political and entrepreneurial career, in 1985 Rebecca acquired five FM radio stations and upgraded each to become Top-100 market properties.
Then, in 1988 she founded Lambert Communications, creating what became the largest multi-channeled, broadcast satellite network serving U.S. hospitals. Subsequently in 2001 she led funds acquisition for Shaker Investments to $1 billion under management.
Prior to these entrepreneurial initiatives, Rebecca began her career managing grass-roots political strategy for statewide campaigns, first in Vermont and then in Wyoming for Senator Malcolm Wallop’s upset victory in 1976, after which she served as chief of staff for both Senator Ted Stevens’ national Republican senatorial committee and for Senator Wallop. Subsequently she was appointed deputy assistant secretary, Department of Energy; and then associate deputy secretary, Department of Commerce, where she initiated the federal government’s first use of a memorandum of understanding related to Brazilian hydro projects.
In the civic sector, Rebecca was president of the Bellevue Hospital Association in New York; an associate trustee of the NYU Medical Center Board; and a member of both the Harvard Women’s Leadership Board and the Women’s Forum of New York.


NED Biosystems is thrilled to announce the appointment to its Board of Directors of distinguished entrepreneur, investor, and global philanthropist, Yanchun “Lily” Li. Ms. Li brings an international strategic focus to the Board. Guided by her global vision and humanistic values, Ms. Li has decades of experience building bridges between business, academia, and humanitarian causes – creating meaningful impact. Her expertise will enhance NED’s ability to support cancer patients worldwide.
NED Biosystems strengthened its Board of Directors with the appointment of a highly accomplished physician-scientist and biotechnology executive, José Trevejo, MD, PhD. The appointment of Dr. Trevejo, who has led organizations in the development of high impact medicines spanning multiple therapeutic areas, will bring a key life sciences expertise to the Board. His current work in developing transformative therapies using nature’s chemistry is also well aligned with NED’s own incorporation of natural substances into systems-based approaches that promise to transform how cancer patients are treated globally.
NED Biosystems has added key finance expertise to its Board of Directors through the recent appointment of John Thomas, CPA. Mr. Thomas brings to the board almost 40 years of executive experience in corporate finance. He has guided life sciences companies through the full spectrum of development from the formation of the company and the initial fund-raising efforts to the sale transaction or initial public offering. This wealth of experience will be invaluable to NED as it moves through its upcoming financing round and into clinical development.
NED congratulates our Board Director Carolina Alarco on receiving LabCentral Ignite’s inaugural Ted W. Love Award for Individual Impact on Life Sciences Diversity, Equity, & Inclusion at the first annual bioDiversity Summit Awards Dinner on September 28, 2022.
Ms. Forlenza, a NY State Licensed CPA, brings over 35 years of experience in corporate finance to the Board. She has a proven track record leading privately and publicly held companies from inception to growth and profitability. Since founding LC Forlenza Advisory Services in 1987, she has advised over 250 long-tenured clients across the globe on a wide range of financial matters including tax and audit strategy, forensic accounting, mergers, and reporting. Throughout the 1980s and early 1990s, Ms. Forlenza led audit and tax relationships with international audit firms on behalf of global brokerage firms Bierbaum-Martin Inc and International Exchange Partners. She led operations for these firms in London, Dusseldorf, and New York. Ms. Forlenza has held numerous board positions advising companies on audit and tax-related matters and currently serves as Chair of the Audit Committee for the Board of Innodata Inc. She holds a Certificate in Forensic Accounting from NYU and BBA in Accounting from Iona College where she was the first and only female accounting major in her graduating class, and she has completed Executive Training Programs at Harvard Business School and The Wharton School.
Dr. El-Bardeesy is Associate Professor of Medicine at the Harvard Medical School and a leading authority on the causes of cancer. Dr. El-Bardeesy also serves as the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board Co-Chair. Dr. El-Bardeesy additionally is Assistant Professor at Massachusetts General Hospital Cancer Center and is an instructor at the Dana-Farber Cancer Institute. Dr. El-Bardeesy is widely published on the molecular and cellular mechanisms that drive certain types of cancer.
Dr. Kurzrock is Professor of Medicine and Associate Director for Clinical Sciences at the University of San Diego Moore Cancer Center. She leads the Center’s clinical trial programs and heads its recently established Center for Personalized Cancer Therapy. Dr. Kurzrock’s distinguished track record includes leading one of the largest phase one clinical trial programs at the University of Texas MD Anderson Cancer Center, where she spearheaded an innovative approach that utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized the possibility for response.